GLP-1 Receptor Agonists and Your Heart: What the Evidence Shows About Cardiovascular Protection

Most patients come to me already knowing that semaglutide and the other GLP-1 receptor agonists help with weight and diabetes. Fewer know that these same medicines have quietly become some of the most important cardiovascular drugs of the last decade. In study after study, in patients with and without diabetes, they reduce heart attacks, strokes, and cardiovascular deaths. For the right patient, starting one is a genuinely heart-protective decision, not just a weight or glucose decision.

This article walks through how these medicines work inside the cardiovascular system, what the major outcomes trials actually showed, which patients benefit most, and how I think about adding or stopping a GLP-1 in my own practice. My goal is that by the end you understand enough to have a concrete conversation with your own cardiologist or primary care doctor about whether one of these drugs fits into your care.

What GLP-1 Receptor Agonists Are

Glucagon-like peptide-1, or GLP-1, is a hormone your gut releases in response to a meal. It tells the pancreas to release more insulin, tells the liver to make less glucose, slows how quickly the stomach empties, and signals the brain that you're full. The GLP-1 your body makes breaks down in minutes. GLP-1 receptor agonists are engineered molecules that mimic this signal but last much longer, typically a full week with the modern weekly formulations.

The drugs you most commonly see in this class are semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound), which is technically a dual GLP-1 and GIP agonist. They all share the same core mechanism, but the cardiovascular evidence is strongest for semaglutide, liraglutide, and dulaglutide because those are the agents with dedicated cardiovascular outcomes trials in their file.

How GLP-1 Drugs Protect the Heart and Vasculature

The cardiovascular benefit is not a single effect. It's a bundle of downstream changes that all point in the same direction.

First, there's meaningful weight loss. Average reductions run about 9 to 15 percent of body weight on high-dose semaglutide and roughly 15 to 22 percent on tirzepatide, with smaller but still meaningful losses on liraglutide and dulaglutide. Weight loss of that magnitude favorably shifts blood pressure, lipids, inflammation, and sleep apnea burden, each of which independently drives cardiovascular risk.

Second, there's direct glucose lowering. In patients with type 2 diabetes, hemoglobin A1c drops by roughly 1 to 2 percentage points. Tighter glucose control by itself is modestly cardioprotective, though the effect is clearly not large enough to explain the size of the benefit seen in the outcomes trials.

Third, there are direct effects on the vessel wall and on inflammation. GLP-1 receptors are present on endothelial cells, vascular smooth muscle, and immune cells. Activating them lowers systemic inflammatory markers like C-reactive protein by roughly 37 to 43 percent, a reduction comparable to what statins produce, and this translates into better endothelial function and reduced plaque progression in imaging substudies. This is probably the piece that explains why benefit shows up in non-diabetic patients too, because you can't explain it through glucose lowering alone.

Fourth, there's a small but real blood pressure reduction, roughly 2 to 6 mmHg of systolic pressure, a small improvement in LDL and triglycerides, and a modest decline in visceral and epicardial fat. None of these alone would change outcomes, but stacked on top of the weight, glucose, and anti-inflammatory effects, they add up.

What the Outcomes Trials Actually Showed

The reason cardiologists now routinely recommend these drugs is a set of large, well-run trials that enrolled patients at high cardiovascular risk and followed them for years. A few of them set the field.

LEADER randomized more than 9,300 patients with type 2 diabetes and either established cardiovascular disease or high risk for it to liraglutide versus placebo. Over a median 3.8 years of follow-up, liraglutide reduced the primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 13 percent. Cardiovascular death alone dropped by 22 percent and all-cause death by 15 percent. This was the first clear signal that the class was doing something beyond glucose lowering.

SUSTAIN-6 tested weekly semaglutide against placebo in a similar diabetes population and showed a 26 percent reduction in the same composite endpoint, driven mostly by a 39 percent reduction in nonfatal stroke. Benefits appeared within the first year.

REWIND studied dulaglutide in a broader population that included many primary prevention patients. It reduced the composite cardiovascular endpoint by 12 percent over a median 5.4 years, with particularly strong effects on stroke. REWIND expanded the evidence base from "diabetes with established cardiovascular disease" to "diabetes with high risk," which is a much larger population.

SELECT broke entirely new ground. It enrolled over 17,000 patients with established cardiovascular disease, a body mass index of 27 or higher, and crucially, no diabetes. Semaglutide 2.4 mg weekly reduced the primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 20 percent compared with placebo over a median 40 months of follow-up. This was the first time a weight-loss drug was shown to reduce hard cardiovascular outcomes in a non-diabetic population. It fundamentally changed how cardiologists think about obesity as a modifiable cardiovascular risk factor.

Meta-analyses that pool these trials find a consistent 12 to 14 percent relative reduction in major adverse cardiovascular events across the class, with the biggest effects on stroke and cardiovascular mortality. The most comprehensive synthesis to date, a 2025 meta-analysis of nearly 100,000 patients across 21 randomized trials, confirmed these benefits with high-certainty evidence and showed they hold up across patients with and without diabetes, with and without kidney disease, and with and without established heart failure. The number needed to treat to prevent one major event over about three years is roughly 50 to 75 in higher-risk populations, which is in the same range as modern cholesterol-lowering therapy.

Kidney Protection Comes With It

The outcomes trials also revealed consistent kidney benefits. Across LEADER, SUSTAIN-6, and REWIND, progression of albuminuria was reduced by 15 to 26 percent. The dedicated FLOW trial randomized more than 3,500 patients with type 2 diabetes and chronic kidney disease to semaglutide versus placebo and was stopped early because of a 24 percent reduction in the composite kidney endpoint of kidney failure, substantial loss of kidney function, or kidney or cardiovascular death. Cardiovascular deaths also dropped 29 percent in FLOW. For patients with diabetes plus chronic kidney disease, GLP-1 agonists have now joined SGLT2 inhibitors as kidney-protective as well as heart-protective.

Who Benefits Most

I think about candidacy for cardiovascular indications in tiers.

The clearest benefit is in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, meaning a prior heart attack, stroke, coronary artery disease on angiography, or symptomatic peripheral arterial disease. For these patients, a GLP-1 agonist and an SGLT2 inhibitor are now considered first-line additions alongside metformin, independent of A1c. Current American Diabetes Association and American College of Cardiology guidance both reflect this.

The second tier is type 2 diabetes with high cardiovascular risk but no prior event, which is where REWIND is most relevant. The benefit is present but somewhat smaller on an absolute basis.

The third tier, opened by SELECT, is patients without diabetes who have established cardiovascular disease and a BMI of 27 or higher. This is a large group. For many of my patients who have had a stent or bypass, who are overweight and have stubborn blood pressure or lipids, semaglutide 2.4 mg is now a real option for cardiovascular risk reduction. I talk about it the same way I talk about a second lipid-lowering agent.

Patients with chronic kidney disease and diabetes benefit from both the cardiovascular and renal effects, so that group is now essentially a separate indication.

Heart failure is more nuanced. GLP-1 agonists have not been shown to reduce heart failure hospitalizations in HFrEF, and in one small trial of liraglutide in advanced HFrEF, there was a signal of possible harm. The current guideline recommendation is to avoid or use cautiously in patients with severely reduced ejection fraction. In HFpEF, by contrast, semaglutide 2.4 mg reduced symptoms, weight, 6-minute walk distance, CRP, and NT-proBNP in the STEP-HFpEF and STEP-HFpEF DM trials. A pooled analysis of SELECT, FLOW, and the two STEP-HFpEF trials showed semaglutide cut the composite of cardiovascular death or worsening heart failure events by 31 percent in patients with HFpEF and obesity. For this population, semaglutide 2.4 mg is now reasonable, and the 2025–2026 ADA guidance explicitly endorses it.

Practical Side Effects and Management

The most common side effects are gastrointestinal: nausea, early satiety, constipation, occasional vomiting or diarrhea. They are worst in the first weeks and during dose escalation. Starting low, titrating slowly over 8 to 16 weeks, eating smaller meals, avoiding very fatty meals, and staying hydrated all help. Most patients who tolerate the first 8 weeks stay on the drug long-term.

Hypoglycemia is rare unless the patient is also on insulin or a sulfonylurea, which may need to be reduced when the GLP-1 is started. Pancreatitis is uncommon but listed as a precaution; I stop the drug if a patient develops severe unexplained abdominal pain and check a lipase. Large pooled analyses of the outcomes trials have not confirmed an increased risk of pancreatitis or pancreatic cancer, but the convention to hold the drug if pancreatitis is suspected has not changed. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2 are the only boxed-warning contraindications, extrapolated from rodent data that has not been reproduced in human cohort studies. Other things I watch for: gallbladder disease runs roughly a third higher on these drugs, probably related to rapid weight loss; heart rate rises by two to four beats per minute without any demonstrated clinical consequence; and the SUSTAIN-6 trial reported a retinopathy signal in patients with long-standing diabetes whose glucose dropped rapidly, though this has not recurred in the non-diabetic SELECT or the CKD-focused FLOW trials. A history of severe gastroparesis is a reason to avoid these drugs.

Muscle loss accompanies weight loss on these drugs, probably proportional to the caloric deficit. I spend real time in visits talking about resistance training and adequate protein intake, because the weight loss is most useful when it preserves muscle. I also ask about how the patient is eating. Losing weight by genuinely eating less is not the same physiologic picture as losing weight while forcing down inadequate protein or skipping meals, and the second pattern worries me more.

When to Start, When to Stop

I typically start a GLP-1 agonist for cardiovascular indications when a patient fits one of the tiers above, when they are otherwise maximally optimized on standard therapy, and when they are motivated to stick with a weekly injection for years. For the diabetes indications, the drug is often added at moderate doses. For the dedicated cardiovascular weight-loss indication from SELECT, the target is typically semaglutide 2.4 mg weekly, which takes several months to reach.

I do not stop these drugs just because a patient has reached their goal weight. Weight regain is the expected natural history after stopping, and cardiovascular risk tracks with weight. I reframe the conversation the way I do for antihypertensives: the target is not a short course to fix a number, it's long-term management of a chronic risk factor. If cost is a barrier, which it often is, we talk about the cheapest available option in the class, manufacturer coupons, and, when possible, shifting to a less expensive GLP-1 that still has cardiovascular evidence.

What This Means for You

If you have type 2 diabetes and cardiovascular disease, you should be on both a GLP-1 agonist and an SGLT2 inhibitor unless there's a clear reason not to. If you have cardiovascular disease and a BMI of 27 or higher, semaglutide 2.4 mg deserves a real conversation with your doctor. If you have diabetes and kidney disease, both drug classes are now considered kidney-protective as well, and starting them is no longer optional in most guidelines.

These medicines are not trivial to start, tolerate, or pay for, but for the right patient they move the needle on exactly the outcomes we spend our whole careers trying to prevent.

References

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.

2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.

3. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121-130.

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.

5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.

6. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084.

7. Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials. Lancet. 2024.

8. Galli M, Benenati S, Laudani C, et al. Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients. J Am Coll Cardiol. 2025.

9. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026.

10. American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: standards of care in diabetes-2026. Diabetes Care. 2026.